Treating Tobacco Use and Dependence
Quick Reference Guide for Clinicians
Contents
To All Clinicians
Purpose
Key Findings
Tobacco Dependence as a Chronic Health Condition
Tobacco Users Willing To Quit
Tobacco Users Unwilling To Quit
Tobacco Users Who Recently Quit
New Recommendations in the PHS-Sponsored Clinical Practice Guideline—Treating Tobacco Use and Dependence: 2008 Update
Conclusion
Guideline Availability
To All Clinicians
The Public Health Service-sponsored Clinical Practice Guideline, Treating Tobacco Use and Dependence: 2008 Update , on which this Quick Reference Guide for Clinicians is based was developed by a multidisciplinary, non-Federal panel of experts, in collaboration with a consortium of tobacco cessation representatives, consultants, and staff. Panel members, Federal liaisons, and guideline staff were as follows:
Guideline Panel
Michael C. Fiore, M.D., M.P.H. (Panel Chair)
Carlos Roberto Jaén, MD, PhD, FAAFP (Panel Vice Chair)
Timothy B. Baker, PhD (Senior Scientist)
William C. Bailey, M.D.
Neal Benowitz, MD
Susan J. Curry, PhD
Sally Faith Dorfman, M.D., MSHSA
Erika S. Froelicher, PhD, RN, MA, MPH
Michahael G. Goldstein, M.D.
Cheryl G. Healton, DrPH
Patricia Nez Henderson, MD, MPH
Richard B. Heyman, M.D.
Howard K. Koh, MD, MPH, FACP
Thomas E. Kottke, M.D., M.S.P.H.
Harry A. Lando, Ph.D.
Robert E. Mecklenburg, D.D.S., M.P.H.
Robin J. Mermelstein, PhD
Patricia Dolan Mullen, Dr.P.H.
.C. Tracy Orleans, PhD
Lawrence Robinson, M.D., M.P.H.
Maxine L. Stitzer, Ph.D.
Anthony C. Tommasello, M.S.
Louise Villejo, M.P.H., C.H.E.S.
Mary Ellen Wewers, Ph.D., R.N.
Guideline Liaisons
Ernestine W. Murray, RN, BSN, MAS (Project Officer), Agency for
Healthcare Research and Quality
Glenn Bennett, MPH, CHES, National Heart, Lung, and Blood Institute
Stephen Heishman, PhD, National Institute on Drug Abuse
Corinne Husten, MD, MPH, Centers for Disease Control and Prevention
Glen Morgan, PhD, National Cancer Institute
Christine Williams, MEd, Agency for Healthcare Research and Quality
Guideline Staff
Bruce Christiansen, PhD (Project Director)
Megan E. Piper, PhD (Project Scientist)
Victor Hasselblad, PhD (Project Statistician)
David Fraser, MS (Project Coordinator)
Wendy Theobald, PhD (Editorial Associate)
Michael Connell, BS (Database Manager)
Cathlyn Leitzke, MSN, RN-C (Project Researcher)
An explicit, science-based methodology was employed along with expert clinical judgment to develop recommendations on treating tobacco use and dependence. Extensive literature searches were conducted and critical reviews and syntheses were used to evaluate empirical evidence and significant outcomes. Peer review was undertaken to evaluate the validity, reliability, and utility of the guideline in clinical practice. Go to the complete Guideline (available at https://www.hhs.gov/surgeongeneral/priorities/tobacco/index.html) for the methods, peer reviewers, references, and financial disclosure information.
This Quick Reference Guide for Clinicians presents summary points from the Clinical Practice Guideline. The guideline provides a description of the development process, thorough analysis and discussion of the available research, critical evaluation of the assumptions and knowledge of the field, and more complete information for health care decisionmaking. Decisions to adopt particular recommendations from either publication must be made by practitioners in light of available resources and circumstances presented by the individual patient.
As clinicians, you are in a frontline position to help your patients by asking two key questions: "Do you smoke?" and "Do you want to quit?" followed by use of the recommendations in this Quick Reference Guide for Clinicians.
Abstract
This Quick Reference Guide for Clinicians contains strategies and recommendations from the Public Health Service-sponsored Clinical Practice Guideline, Treating Tobacco Use and Dependence: 2008 Update. . The guideline was designed to assist clinicians; smoking cessation specialists; and healthcare administrators, insurers, and purchasers in identifying and assessing tobacco users and in delivering effective tobacco dependence interventions. It was based on an exhaustive systematic review and analysis of the extant scientific literature from 1975-2007 and uses the results of more than 50 meta-analyses.
This Quick Reference Guide for Clinicians summarizes the guideline strategies for providing appropriate treatments for every patient. Effective treatments for tobacco dependence now exist, and every patient should receive at least minimal treatment every time he or she visits a clinician. The first step in this process—identification and assessment of tobacco use status—separates patients into three treatment categories:
- Tobacco users who are willing to quit should receive intervention to help in their quit attempt.
- Those who are unwilling to quit now should receive interventions to increase their motivation to quit.
- Those who recently quit using tobacco should be provided relapse prevention treatment.
Suggested CitationThis document is in the public domain and may be used and reprinted without special permission. The Public Health Service appreciates citation as to source, and the suggested format is provided below: Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Quick Reference Guide for Clinicians. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. April 2009. |
Purpose
Tobacco is the single greatest cause of disease and premature death in America today, and is responsible for more than 435,000 deaths annually. About 20 percent of adult Americans currently smoke, and 4,000 children and adolescents smoke their first cigarette each day. The societal costs of tobacco-related death and disease approach $96 billion annually in medical expenses and $97 billion in lost productivity. However, more then 70 percent of all current smokers have expressed a desire to stop smoking; if they successfully quit, the result will be both immediate and long-term health improvements. Clinicians have a vital role to play in helping smokers quit.
The analyses within the Clinical Practice Guideline Treating Tobacco Use and Dependence: 2008 Update demonstrated that efficacious treatments for tobacco users exist and should become a part of standard care giving. Research also shows that delivering such treatments is cost-effective. In summary, the treatment of tobacco use and dependence presents the best and most cost-effective opportunity for clinicians to improve the lives of millions of Americans nationwide.
Key Findings
The guideline identified a number of key findings that clinicians should use:
- Tobacco dependence is a chronic disease that often requires repeated intervention and multiple attempts to quit. Effective treatments exist, however, that can significantly increase rates of long-term abstinence.
- It is essential that clinicians and healthcare delivery systems consistently identify and document tobacco use status and treat every tobacco user seen in a healthcare setting.
- Tobacco dependence treatments are effective across a broad range of populations. Clinicians should encourage every patient willing to make a quit attempt to use the recommended counseling treatments and medications in the Guideline.
- Brief tobacco dependence treatment is effective. Clinicians should offer every patient who uses tobacco at least the brief treatments shown to be effective in the Guideline.
- Individual, group and telephone counseling are effective and their effectiveness increases with treatment intensity. Two components of counseling are especially effective and clinicians should use these when counseling patients making a quit attempt:
- Practical counseling (problem-solving/skills training).
- Social support delivered as part of treatment.
- There are numerous effective medications for tobacco dependence and clinicians should encourage their use by all patients attempting to quit smoking, except when medically contraindicated or with specific populations for which there is insufficient evidence of effectiveness (i.e., pregnant women, smokeless tobacco users, light smokers and adolescents).
- Seven first-line medications (5 nicotine and 2 non-nicotine) reliably increase long-term smoking abstinence rates:
- Bupropion SR
- Nicotine gum
- Nicotine inhaler
- Nicotine lozenge
- Nicotine nasal spray
- Nicotine patch
- Varenicline
- Clinicians should also consider the use of certain combinations of medications identified as effective in the Guideline.
- Seven first-line medications (5 nicotine and 2 non-nicotine) reliably increase long-term smoking abstinence rates:
- Counseling and medication are effective when used by themselves for treating tobacco dependence. However, the combination of counseling and medication is more effective than either alone. Thus, clinicians should encourage all individuals making a quit attempt to use both counseling and medication.
- Telephone quitline counseling is effective with diverse populations and has broad reach. Therefore, clinicians and healthcare delivery systems should both ensure patient access to quitlines and promote quitline use.
- If a tobacco user is currently unwilling to make a quit attempt, clinicians should use the motivational treatments shown in the Guideline to be effective in increasing future quit attempts.
- Tobacco dependence treatments are both clinically effective and highly cost-effective relative to interventions for other clinical disorders. Providing coverage for these treatments increases quit rates. Insurers and purchasers should ensure that all insurance plans include the counseling and medication identified as effective in the Guideline as covered benefits.
Tobacco Dependence as a Chronic Health Condition
Tobacco dependence is a chronic health condition that often requires multiple, discrete interventions by a clinician or team of clinicians. The "5 A's" of treating tobacco dependence (Ask, Advise, Assess, Assist, and Arrange follow-up) is a useful way to understand tobacco dependence treatment and organize the clinical team to deliver that treatment. While a single clinician can provide all 5 A's, it is often more clinically and cost-effective to have the 5 A's implemented by a team of clinicians and ancillary staff. However when a team is used, coordination of efforts is essential with a single clinician retaining overall responsibility for the interventions. Clinician extenders such as quit lines, Web-based interventions, local quit programs and tailored, self-help materials can often be, and should be, incorporated into the 5 A's approach. These treatment extenders can make clinical interventions more efficient.
This Quick Reference Guide for Clinicians is organized around the 5 A's. However, the clinical situation may suggest delivering these components in a different order or format. The following sections address the three main groups of tobacco users:
- Those who are willing to quit.
- Those who are unwilling to quit now.
- Those who recently quit.
This Quick Reference Guide for Clinicians is based on Guideline findings and includes many tables directly from the Guideline.
Table 1. The "5 A's" model for treating tobacco use and dependence
Ask about tobacco use | Identify and document tobacco use status of every patient at every visit. |
Advise to quit | In a clear, strong and personalized manner urge every tobacco user to quit. |
Assess |
For current tobacco user, is the tobacco user willing to make a quit attempt at this time? For the ex-tobacco user, how recent did you quit and are there any challenges to remaining abstinent? |
Assist |
For the patient willing to make a quit attempt, offer medication and provide or refer for counseling or additional behavioral treatment to help the patient quit. For patients unwilling to quit at this time, provide motivational interventions designed to increase future quit attempts. For the recent quitter and any with remaining challenges, provide relapse prevention. |
Arrange | All those receiving the previous A's should receive followup. |
Select for Figure 1: The "5 A's": Treating Tobacco Dependence as a Chronic Disease.
Tobacco Users Willing To Quit
The "5 A's," Ask, Advise, Assess, Assist, and Arrange, are designed to be used with the smoker who is willing to quit.
Table 2. Ask—Systematically identify all tobacco users at every visit
Action | Strategies for Implementation |
---|---|
Implement an office-wide system that ensures that, for every patient at every clinic visit, tobacco-use status is queried and documented.a | Expand the vital signs to include tobacco use or use an alternative universal identification system.b |
Vital Signs Blood Pressure:__________________________________________ Pulse: _____________________ Weight: _____________________ Temperature: ____________________________________________ Respiratory Rate: ________________________________________ Tobacco Use: (circle one) Current Former Never |
a Repeated assessment is not necessary in the case of the adult who has never used tobacco or has not used tobacco for many years and for whom this information is clearly documented in the medical record.
b Alternatives to expanding the vital signs include using tobacco use status stickers on all patient charts or indicating tobacco use status via electronic medical records or computerized reminder systems.
Table 3. Advise—Strongly urge all tobacco users to quit
Action | Strategies for Implementation |
---|---|
In a clear, strong, and personalized manner, urge every tobacco user to quit. | Advice should be:
|
Table 4. Assess—Determine willingness to make a quit attempt
Action | Strategies for Implementation |
---|---|
Assess every tobacco user's willingness to make a quit attempt at this time | Assess patient's willingness to quit: "Are you willing to give quitting a try?"
|
Table 5. Assist—Aid the patient in quitting (provide counseling and medication)
Action | Strategies for Implementation |
---|---|
Help the patient with a quit plan. | A patient's preparations for quitting:
|
Recommend the use of approved medication, except when contraindicated or with specific populations for which there is insufficient evidence of effectiveness (i.e., pregnant women, smokeless tobacco users, light smokers, and adolescents). | Explain how these medications increase quitting success and reduce withdrawal symptoms. FDA-approved medications include: bupropion SR, nicotine gum, nicotine inhaler, nicotine lozenge, nicotine nasal spray, nicotine patch, and varenicline. There is insufficient evidence to recommend medication for pregnant women, adolescents, smokeless tobacco users, and light smokers (< 10 cigarettes/day). |
Provide practical counseling (problem solving/skill training). |
|
Provide intratreatment social support. | Provide a supportive clinical environment while encouraging the patient in his or her quit attempt. "My office staff and I are available to assist you." "I'm recommending treatment that can provide ongoing support." |
Help patient obtain extra-treatment social support. |
|
Provide supplementary materials, including information on quitlines. |
|
Assist Component—Three Types of Counseling
Counseling should include teaching practical problem solving skills and providing support and encouragement.
Table 6. Common elements of practical counseling
Practical counseling (problem-solving/skills training) treatment component | Examples |
---|---|
Recognize danger situations—Identify events, internal states, or activities that increase the risk of smoking or relapse. |
|
Develop coping skills—Identify and practice coping or problem-solving skills. Typically, these skills are intended to cope with danger situations. |
|
Provide basic information—Provide basic information about smoking and successful quitting. |
|
Table 7. Common elements of supportive counseling
Supportive treatment component | Strategies for implementation |
---|---|
Encourage the patient in the quit attempt. |
|
Communicate caring and concern. |
|
Encourage the patient to talk about the quitting process. | Ask about:
|
Table 8. Providing Counseling—Frequently Asked Questions
Question | Answer |
---|---|
My patient doesn't want counseling, only medication. What should I do? | Point out that counseling plus medication works better than medication alone. Explain that the goal of counseling (or coaching) is to provide the practical skills that increase the likelihood of quitting successfully. Use the motivational interventions designed for tobacco users who do not want to quit to encourage your patient to accept counseling. Emphasize the inconsistency between not using effective counseling for something as important and difficult as quitting tobacco. If the patient still declines counseling, consider providing medication alone because medication alone has been shown to be effective. During followup, continue to provide the key elements of counseling: problem solving, practical skills, and support. |
My patient wants to use a method of quitting not known to be effective such as acupuncture, hypnosis, or laser therapy. What do I do? | Ask the patient to consider increasing the success odds of his/her quit attempt by augmenting his/her method of quitting with evidence-based medication and counseling. Do not denigrate any attempt to quit. If the patient declines, support his/her effort, but ask for an agreement that, should it not be successful, the patient will consider evidence-based methods in the future, including medication and counseling. |
My patient is concerned about gaining weight. | Recommend that the patient start or increase physical activity. For example, take a walk at break time rather than smoke and/or walk at lunch. Also see medication recommendations for such patients. |
My patient is concerned about using NRT because he/she believes nicotine to be one of the harmful ingredients in tobacco products. | Explain that medicinal nicotine by itself is relatively safe. Emphasize that the 4,000 chemicals in cigarette smoke, including about 40 carcinogens, cause the harm from smoking. Also, medicinal nicotine has been proven to greatly reduce withdrawal symptoms in many people. |
My patient does not want to use medication because of:
|
Point out:
|
My patient says his/her life is too stressful to quit smoking and he/she needs to smoke to relax. | Acknowledge that for many people smoking is one way to deal with stress. But it is only one way. Counseling will help him/her develop new ways to cope. It will take some time. At first the new ways may feel less effective but the longer the patient is away from smoking, the easier it will be to handle stress without smoking. Also his/her health will be so much better. |
My patient says he/she has been smoking for many (20, 30, or more) years without any health problems, plus his/her grandfather smoked two packs a day and lived to be 105. | Consider saying something like, "There are certainly people who smoke for many years without apparent tobacco-related diseases. But about half of people who smoke will die from a tobacco-related illness. The average smoker lives 10 years less than non-smokers. I know it is hard to quit, but is that any reason to gamble with your health when you know that there is a 50-percent chance you will die from a tobacco-related disease?" |
Table 9. Suggestions for the clinical use of medication for tobacco dependence treatment a
Medication | Cautions/Warnings | Side Effects | Dosage | Use | Availability (check insurance) |
---|---|---|---|---|---|
Bupropion SR 150 |
Not for use if you:
|
|
|
Start 1-2 weeks before quit date; use 2 to 6 months |
Prescription only
|
Nicotine Gum (2 mg or 4 mg) |
|
|
|
Up to 12 weeks or as needed |
OTC only:
|
Nicotine Inhaler | May irritate mouth/ throat at first (but improved with use) | Local irritation of mouth and throat |
|
Up to 6 months; taper at end | Prescription only: Nicotrol inhaler |
Nicotine Lozenge (2 mg or 4 mg) |
|
|
|
3-6 months |
OTC only:
|
Nicotine Nasal Spray |
|
Nasal irritation |
|
3-6 months; taper at end | Prescription only: Nicotrol NS |
Nicotine Patch | Do not use if you have severe eczema or psoriasis |
|
|
8-12 weeks |
OTC or prescription:
|
Varenicline |
Use with caution in patients:
|
|
|
Start 1 week before quit date; use 3-6 months | Prescription only: Chantix |
Combinations:
|
|
Refer to individual medications above. | Refer to individual medications above. | Refer to information provided above. | Refer to information provided above. |
a Based on the 2008 Clinical Practice Guideline: Treating Tobacco Use and Dependence, U.S. Public Health Service, May 2008. Refer to the FDA Web site for additional dosing and safety information, including safety protocols.
Table 10. Providing Medication—Frequently Asked Questions
Question | Answer |
---|---|
Who should receive medication for tobacco use? Are there groups of smokers for whom medication has not been shown to be effective? | All smokers trying to quit should be offered medication, except where contraindicated or for specific populations for which there is insufficient evidence of effectiveness (i.e., pregnant women, smokeless tobacco users, light smokers, and adolescents). |
What are the recommended first-line medications? | All seven of the FDA-approved medications for treating tobacco use are recommended: bupropion SR, nicotine gum, nicotine inhaler, nicotine lozenge, nicotine nasal spray, the nicotine patch, and varenicline. The clinician should consider the first-line medications shown to be more effective than the nicotine patch alone: 2 mg/day varenicline or the combination of long-term nicotine patch use + ad libitum NRT. Unfortunately, there are no well-accepted algorithms to guide optimal selection among the first-line medications. |
Are there contraindications, warnings, precautions, other concerns, and side effects regarding the first-line medications recommended in this Guideline Update? | All seven FDA-approved medications have specific contraindications, warnings, precautions, other concerns, and side effects. Please refer to FDA package inserts and updates for complete information on how to use the medication safely. |
What other factors may influence medication selection? | Pragmatic factors may also influence selection such as insurance coverage or out-of-pocket patient costs, likelihood of adherence, dentures when considering the gum, or dermatitis when considering the patch. |
Is a patient's prior experience with a medication relevant? | Prior successful experience (sustained abstinence with the medication) suggests that the medication may be helpful to the patient in a subsequent quit attempt, especially if the patient found the medication to be tolerable and/or easy to use. However, it is difficult to draw firm conclusion from prior failure with a medication. Some evidence suggests that retreating relapsed smokers with the same medication produces small or no benefit while other evidence suggests that it may be of substantial benefit. |
What medications should a clinician use with a patient who is highly nicotine dependent? | The higher dose preparations of nicotine gum, patch, and lozenge have been shown to be effective in highly dependent smokers. Also, there is evidence that combination NRT therapy may be particularly effective in suppressing tobacco withdrawal symptoms. Thus, it may be that NRT combinations are especially helpful to highly dependent smokers or those with a history of severe withdrawal. |
Is gender a consideration in selecting a medication? | There is evidence that NRT can be effective with both sexes; however, evidence is mixed as to whether NRT is less effective in women than men. This may encourage the clinician to consider use of another type of medication with women such as bupropion SR or varenicline. |
Are cessation medications appropriate for light smokers (i.e., <10 cigarettes/day)? | As noted above, cessation medications have not been shown to be beneficial to light smokers. However, if NRT is used with light smokers, clinicians may consider reducing the dose of the medication. No adjustments are necessary when using bupropion SR or varenicline. |
When should second-line agents be used for treating tobacco dependence? | Consider prescribing second-line agents (clonidine and nortriptyline) for patients unable to use first-line medications because of contraindications or for patients for whom the group of first-line medications has not been helpful. Assess patients for the specific contraindications, precautions, other concerns, and side effects of the second-line agents. Please refer to FDA package inserts for this information. |
Which medications should be considered with patients particularly concerned about weight gain? | Data show that bupropion SR and nicotine replacement therapies, in particular 4 mg nicotine gum and 4 mg nicotine lozenge, delay, but do not prevent, weight gain. |
Are there medications that should be especially considered in patients with a past history of depression? | Bupropion SR and nortriptyline appear to be effective with this population, but nicotine replacement medications also appear to help individuals with a past history of depression. |
Should nicotine replacement therapies be avoided in patients with a history of cardiovascular disease? | No. The nicotine patch in particular has been demonstrated as safe for cardiovascular patients. |
May tobacco dependence medications be used long-term (e.g., up to 6 months)? | Yes. This approach may be helpful with smokers who report persistent withdrawal symptoms during the course of medications, who have relapsed in the past after stopping, or who desire long-term therapy. A minority of individuals who successfully quit smoking use ad libitum NRT medications (gum, nasal spray, inhaler) long term. The use of these medications for up to 6 months does not present a known health risk and developing dependence on medications is uncommon. Additionally, the FDA has approved the use of bupropion SR, varenicline, and some NRT medications for 6-month use. |
Is medication adherence important? | Yes. Patients frequently do not use cessation medications as recommended (e.g., they don't use them at recommended doses or for recommended durations); this may reduce their effectiveness. |
May medications ever be combined? | Yes. Among first-line medications, evidence exists that combining the nicotine patch long term (> 14 weeks) with nicotine gum or nicotine nasal spray, the nicotine patch with the nicotine inhaler, or the nicotine patch with bupropion SR, increases long-term abstinence rates relative to placebo treatments. |
My patient can't afford medications and doesn't have insurance to cover it. What can I do? |
|
Arrange
Tobacco dependence is an addiction. Quitting is very difficult for most tobacco users. It is essential that the patient trying to quit has scheduled followup. This is especially important when the treatment is shared by a team of clinicians and includes treatment extenders such as quitline counseling.
Table 11. Arrange—Ensure followup contact
Action | Strategies for implementation |
---|---|
Arrange for followup contacts, either in person or via telephone. |
|
Tobacco Users Unwilling to Quit at This Time
Ask, Advise, and Assess every tobacco user following the suggestions in Tables 2-4. If the patient is unwilling to make a quit attempt at this time, use the motivational strategies that follow to increase the likelihood of quitting in the future.
Assist
Tobacco users who do not want to quit now should be provided with specific interventions designed to increase the likelihood that they will decide to quit. This goal can be achieved through strategies designed to enhance motivation to quit.
Such interventions could incorporate the "5 R's": Relevance, Risk, Rewards, Roadblocks, and Repetition. In these interventions, the clinician can introduce the topic of quitting but it is important that the tobacco users address each topic in their own words. The clinician can then help refine the patient's responses and add to them as needed.
Table 12. Enhancing motivation to quit tobacco—the "5 R's"
Relevance | Encourage the patient to indicate why quitting is personally relevant, being as specific as possible. Motivational information has the greatest impact if it is relevant to a patient's disease status or risk, family or social situation (e.g., having children in the home), health concerns, age, gender, and other important patient characteristics (e.g., prior quitting experience, personal barriers to cessation). |
Risks |
The clinician should ask the patient to identify potential negative consequences of tobacco use. The clinician may suggest and highlight those that seem most relevant to the patient. The clinician should emphasize that smoking low-tar/low-nicotine cigarettes or use of other forms of tobacco (e.g., smokeless tobacco, cigars, and pipes) will not eliminate these risks. Examples of risks are:
|
Rewards |
The clinician should ask the patient to identify potential benefits of stopping tobacco use. The clinician may suggest and highlight those that seem most relevant to the patient. Examples of rewards follow:
|
Roadblocks |
The clinician should ask the patient to identify barriers or impediments to quitting and provide treatment (problem-solving counseling, medication) that could address barriers. Typical barriers might include:
|
Repetition | The motivational intervention should be repeated every time an unmotivated patient visits the clinic setting. Tobacco users who have failed in previous quit attempts should be told that most people make repeated quit attempts before they are successful and that you will continue to raise their tobacco use with them. |
Interventions to increase the likelihood that a tobacco user who does not want to quit will decide to quit can draw upon the principles of motivational interviewing:
Table 13. Motivational interviewing strategies
Express Empathy |
|
Develop Discrepancy |
|
Roll with Resistance |
|
Support Self-Efficacy |
|
Arrange Followup
More than one motivational intervention may be required before the tobacco user who is unwilling to quit commits to a quit attempt. It is essential that the patient trying to quit has scheduled followup. Provide followup at the next visit and additional interventions to motivate and support the decisionmaking process of the patient who is unwilling to quit now.
Tobacco Users Who Recently Quit
Ask every patient at every visit if they use tobacco and his or her status documented clearly in the clinical record (e.g., as part of the vital signs, displayed prominently in the electronic medical record). (Go to Table 2 for more details)
Table 14. Assess former tobacco user relapse potential
Action | Strategies for Implementation |
---|---|
How long has it been since you quit? | Most relapse occurs within the first 2 weeks after the quit date and the risk decreases over time. Tobacco users who have quit very recently should be provided assistance. But the risk for relapse can persist for a long time for many tobacco users. Therefore, assess all former tobacco users, regardless of how long ago they quit, about challenges by asking the question below: |
Do you still have any urges to use tobacco or any challenges to remaining tobacco free? | Any recent quitter or former tobacco users still experiencing challenges should receive assistance. |
Table 15. Assist former tobacco users with encouragement to stay abstinent
Action | Strategies for Implementation |
---|---|
The former tobacco user should receive congratulations on any success and strong encouragement to remain abstinent |
When encountering a recent quitter, use open-ended questions relevant to the topics below to discover if the patient wishes to discuss issues related to quitting:
|
Table 16. Specific challenges and potential responses to the tobacco user who recently quit
Challenges | Responses |
---|---|
Lack of support for cessation |
|
Negative mood or depression |
|
Strong or prolonged withdrawal symptoms |
|
Weight gain |
|
Smoking lapses |
|
Arrange Followup
All patients that have recently quit or still face challenges should receive followup for continued assistance and support.
New Recommendations in the PHS-Sponsored Clinical Practice Guideline—Treating Tobacco Use and Dependence: 2008 Update
Most, but not all, of the new recommendations appearing in the 2008 Update of the Guideline resulted from new meta-analyses of the topics chosen by the Guideline panel.
-
Formats of Psychosocial Treatments
Recommendation: Tailored materials, both print and Web-based, appear to be effective in helping people quit. Therefore, clinicians may choose to provide tailored, self-help materials to their patients who want to quit.
-
Combining Counseling and Medication
Recommendation: The combination of counseling and medication is more effective for smoking cessation than either medication or counseling alone. Therefore, whenever feasible and appropriate, both counseling and medication should be provided to patients trying to quit smoking.
Recommendation: There is a strong relation between the number of sessions of counseling when it is combined with medication and the likelihood of successful smoking abstinence. Therefore, to the extent possible, clinicians should provide multiple counseling sessions, in addition to medication, to their patients who are trying to quit smoking.
-
For Tobacco Users Not Willing To Quit Now
Recommendation: Motivational intervention techniques appear to be effective in increasing a patient's likelihood of making a future quit attempt. Therefore, clinicians should use motivational techniques to encourage smokers who are not currently willing to quit to consider making a quit attempt in the future.
-
Nicotine Lozenge
Recommendation: The nicotine lozenge is an effective smoking cessation treatment that patients should be encouraged to use.
Note: Go to the Guideline and FDA Web site for additional information on the safe and effective use of medication. -
Varenicline
Recommendation: Varenicline is an effective smoking cessation treatment that patients should be encouraged to use.
Note: Go to the Guideline and the FDA Web site for additional information on the safe and effective use of medication. -
Specific Populations
Recommendation: The interventions found to be effective in this Guideline have been shown to be effective in a variety of populations. In addition, many of the studies supporting these interventions comprised diverse samples of tobacco users. Therefore, interventions identified as effective in this Guideline are recommended for all individuals who use tobacco except when medically contraindicated or with specific populations in which medication has not been shown to be effective (pregnant women, smokeless tobacco users, light (<10 cigarettes/day) smokers, and adolescents).
-
Light Smokers
Recommendation: Light smokers should be identified, strongly urged to quit and provided counseling treatment interventions.
Conclusion
Tobacco dependence is a chronic disease that deserves treatment. Effective treatments have now been identified and should be used with every current and former smoker. This Quick Reference Guide for Clinicians provides clinicians with the tools necessary to effectively identify and assess tobacco use, and to treat:
- Tobacco users willing to quit.
- Those who are unwilling to quit at this time.
- Former tobacco users.
There is no clinical treatment available today that can reduce illness, prevent death, and increase quality of life more than effective tobacco treatment interventions.
Guideline Availability
This Guideline is available in several formats suitable for health care practitioners, the scientific community, educators, and consumers.
The Clinical Practice Guideline—Treating Tobacco Use and Dependence: 2008 Update—presents recommendations for health care providers with supporting information, tables and figures.
The Quick Reference Guide for Clinicians is a distilled version of the clinical practice guideline, with summary points for ready reference daily.
Helping Smokers Quit: A Guide for Clinicians is a pocket guide that presents a brief summary of the 5 A’s, including a chart regarding medications.
Help for Smokers and Other Tobacco Users is an informational booklet designed for tobacco users with limited formal education.
The full text of the guideline documents, references, and the meta-analyses references for online retrieval are available by visiting the Surgeon General's Web site.
Single copies of these guideline products and further information on the availability of other derivative products can be obtained by calling any of the following Public Health Service clearinghouses toll-free numbers:
Agency for Healthcare Research and Quality (AHRQ)
800-358-9295
Centers for Disease Control and Prevention (CDC)
800-CDC-1311
National Cancer Institute (NCI)
800-4-CANCER